Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

AbbVie CEO Emphasizes Humira Growth Plans, Potential Of HCV Program

This article was originally published in The Pink Sheet Daily

Executive Summary

AbbVie should appeal to long-term investors due to its sustainable business base and plan to issue and increase dividends over time, says CEO Richard Gonzalez.

You may also be interested in...



Mylan Makes Its Move, Buys Abbott Generics In Tax Inversion Strategy

Mylan will buy Abbott’s non-U.S. developed markets specialty and branded generics business in a stock transaction valued at around $5.3 billion, a deal that will allow it to redomicile in the Netherlands.

AbbVie Sales And Growth Increasingly Dominated By Humira

Since its split from Abbott Laboratories in January, AbbVie has been telling a story of gradually overcoming loss of revenue due to generic-challenged lipid franchise via Humira growth and a promising pipeline. For the first quarter of 2013, Humira generated worldwide sales of $2.244 billion, slightly more than half of the company’s entire revenue base.

Gilead Maintaining Lead Position In Hepatitis C, While Idenix Is Starting Over

Gilead and AbbVie are seen as running neck-and-neck to bring the first all-oral combo of direct-acting antivirals to market in HCV, but Gilead’s regimen is expected to win a larger market share. Idenix is starting over in the nucleoside space, but expects to bring a uridine-based “nuc” into clinical development by mid-year.

Related Content

Topics

Related Companies

UsernamePublicRestriction

Register

PS074832

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel